The possible role of maintenance treatment for primary central nervous system lymphoma

被引:24
作者
Bairey, Osnat [1 ,3 ]
Siegal, Tali [2 ]
机构
[1] Beilinson Med Ctr, Inst Hematol, Davidoff Canc Ctr, Rabin Med Ctr, IL-4941492 Petah Tiqwa, Israel
[2] Beilinson Med Ctr, Neurooncol Ctr, Davidoff Canc Ctr, Rabin Med Ctr, IL-4941492 Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
Maintenance treatment; CNS lymphoma; Primary CNS lymphoma; Metronomic therapy; Targeted therapy; Immune modulating therapy; PRIMARY CNS LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; HIGH-DOSE METHOTREXATE; BRUTON TYROSINE KINASE; RANDOMIZED PHASE-III; WHOLE-BRAIN RADIOTHERAPY; NON-HODGKIN-LYMPHOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS;
D O I
10.1016/j.blre.2018.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor. The prognosis is poor, with high rates of relapse and disease progression after treatment. In addition, PCNSL affects a largely older population, so that a significant proportion of patients are ineligible for intensive therapies and high-dose chemotherapy. The elderly patients are also susceptible to the accelerated and detrimental cognitive side effects of whole-brain irradiation which is an alternative consolidation to high-dose chemotherapy. Maintenance therapy has been shown to be a promising strategy to prolong remission time in other hematopoietic malignancies. Herein, we discuss the place of maintenance treatment in PCNSL in view of perspective obtained from hematological malignancies and non-Hodgkin's lymphoma.
引用
收藏
页码:378 / 386
页数:9
相关论文
共 126 条
[1]   Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model [J].
Abrey, Lauren E. ;
Ben-Porat, Leah ;
Panageas, Katherine S. ;
Yahalom, Joachim ;
Berkey, Brian ;
Curran, Walter ;
Schultz, Christopher ;
Leibel, Steven ;
Nelson, Diana ;
Mehta, Minesh ;
DeAngelis, Lisa M. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5711-5715
[2]   Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis [J].
Abrey, LE ;
Moskowitz, CH ;
Mason, WP ;
Crump, M ;
Stewart, D ;
Forsyth, P ;
Paleologos, N ;
Correa, DD ;
Anderson, ND ;
Caron, D ;
Zelenetz, A ;
Nimer, SD ;
DeAngelis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4151-4156
[3]   Long-term survival in primary CNS lymphoma [J].
Abrey, LE ;
DeAngelis, LM ;
Yahalom, J .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :859-863
[4]   Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience [J].
Alimohamed, Nimira ;
Daly, Andrew ;
Owen, Carolyn ;
Duggan, Peter ;
Stewart, Douglas A. .
LEUKEMIA & LYMPHOMA, 2012, 53 (05) :862-867
[5]   Metronomics: towards personalized chemotherapy? [J].
Andre, Nicolas ;
Carre, Manon ;
Pasquier, Eddy .
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) :413-431
[6]   Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma [J].
Anwer, Saiyed ;
Collings, Freya ;
Trace, Kim ;
Sun, Yongkai ;
Sternberg, Alexander .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) :281-282
[7]   A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma [J].
Arora, Mili ;
Gowda, Sonia ;
Tuscano, Joseph .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (04) :209-221
[8]  
Aw A, 2017, DRUGS AGING, P1
[9]   Sequencing of chronic lymphocytic leukemia therapies [J].
Barrientos, Jacqueline C. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :128-136
[10]   Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL) [J].
Bergner, Nicole ;
Monsef, Ina ;
Illerhaus, Gerald ;
Engert, Andreas ;
Skoetz, Nicole .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (11)